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The  review  covers  the  functional  and  structural  approach  followed  by our  group for more  than  34  years ineywords:
MPIPS
alaria vaccine
the search  for  a  methodology  that  allows  the rational  design  of chemically  synthesised  vaccines.  An  anal-
ogy  between  Odysseus,  the  cunning  hero  of  the  epic poem  Odyssey  by  Homer,  and  the  elusive  Plasmodium
parasite  has  been  made,  to review  our research  group’s  main  considerations  when  developing  a  rational
methodology  for  designing  second  generation,  modiﬁed  peptide-based,  minimal  subunit,  multi-antigen,
multi-stage,  chemically  synthesised  vaccines  against  Plasmodium  falciparum  malaria.ynthetic peptides
odiﬁed peptides
. Introduction
Homer’s Odyssey [1] relates the story of Odysseus, the King of
thaca, who was the cleverest, most daring and intelligent Greek
arrior who participated in the Trojan War. Known as the King
f stratagems and trickery, he convinced Achilles, the King of the
yrmidons (from the Greek ants, so named for their armour and
rganisation in battle) to participate in the War, he designed and
reated the Trojan horse to open up the defences of this impene-
rable city, he made the Cyclops, Polyphemus, drunk and tied his
olleagues to the belly of a ram (camouﬂaging them) to enable them
o pass as such to escape the giant’s physical search after having
linded the giant’s single eye, and he led Polyphemus to the cliff
here the Cyclops threw himself over [1].
Microbes, particularly malarial parasites, like Odysseus, use
nalogous tricks and artiﬁces to survive and escape immune pres-
ure, such as genetic variability, blocking, inhibition, suppression,
amouﬂage (fooling Polyphemus) [2,3], immune system den-
ritic cell apoptosis [4,5] (Polyphemus’ suicide), gene duplications,
eshufﬂing, translocations (Trojan horse) [6–8], interference with
ell differentiation [2,9,10] and many more. However, immuno-
ogical silence may  be the subtlest of such mechanisms [11,12].
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We  have found that key peptides, as illustrated by Plasmodium
protein’s conserved high afﬁnity binding peptides (cHABPs) which
afﬁx themselves to red blood cells (RBC) and hepatocytes to enable
host cell invasion and infection [13–15], are immunologically silent
and invisible to the immune system (blinding Polyphemus); this
will be analysed in greater detail further on.
Only in-depth knowledge of these cHABPs at atomic level,
aimed at modifying them (to render them immunogenic and
protectogenic) will provide the weapons able to overcome such
evasion mechanisms and thus allow a protection-inducing immune
response to be mounted [12].
2. The malaria parasite, the Odysseus of the microbes
Human malaria, mainly that caused by the Plasmodium falcipa-
rum parasite, is a transmittable disease affecting around 200 million
people per year and killing about 650,000 of them annually, espe-
cially children less than 5 years old living in sub-Saharan Africa
[16].
The parasite’s complex life-cycle, elegantly studied in depth by
many groups [7,8,17–19], involves several developmental stages
during which it changes its morphology and molecular expres-
sion. Inoculated by a female Anopheles mosquito bite, larva-like
structures called sporozoites (Spz) (Fig. 1A) use gliding motil-
ity [17] (Fig. 1B) to traverse vascular endothelial, Kupffer and
dendritic cells, halt in hepatocytes having high sulphate concen-
tration in heparan sulphate proteoglycans (HSPG) [17] (Fig. 1C),
and proliferate and differentiate inside infected hepatocytes. This
period of susceptibility to attack by the immune system prior to
tp://creativecommons.org/licenses/by/4.0/).
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Fig. 1. (A) Plasmodium falciparum sporozoite structural features. Immune electron microscopy of a Spz displaying reactivity with anti-CSP antibodies (black dots on the mem-
brane) (left) and schematic view of the Spz showing its invasion machinery and essential organelles (right). PM;  plasma membrane, DGP, dense granules; Mic, micronemes;
Rho,  rhoptry; Ct, cytostome; APR, apical pole ring; N, nucleus; Mit, mitochondria and Ap, apicoplast. Adapted from [92,13]. (B) The sporozoite’s journey inside the mammalian
host  (adapted from [93]). Sporozoites are injected into the skin during an infected Anopheles mosquito’s blood meal where they make use of their gliding motility to subse-
quently enter the bloodstream through a capillary endothelial cell. Spz then along the fenestrated endothelia, cross the sinusoidal cell barrier by traversing a resident Kupffer
cell  (KC), or another hepatocyte before invading the ﬁnal resident hepatocyte (seen in detail in C) [94,95]. Adapted from [93]. Massive replication and differentiation leads
to  erythrocyte-infectious Mrz  formation; these are released into the bloodstream through merosomes [96], thereby entering the P. falciparum intraerythrocyte phase. The
Figure  also indicates some of the main parasite proteins involved in each process. (D) P. falciparum merozoite structural features. Schematic view of the merozoite showing its
essential organelles and the proteins localised in them and involved in Mrz  invasion of RBC [56]. Mrz  invasion of RBCs (adapted from [15]). After an initial contact (E), the Mrz
rolls  over the RBC and reorientates itself toward its apical pole, releases micronemal proteins onto the RBC surface, starts to penetrate it, establishes a tight junction between
the  Mrz  and RBC membrane and releases rhoptry proteins (F), some of which are involved in parasitophorous vacuole (PV) formation (G) [15,19,97]. Asexual replication
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equestration within hepatocytes, lasts from a few minutes to 1 h.
ue to the small number of Spz inoculated during a mosquito bite
100–1000 per infectious bite) and this window of susceptibility,
his is the most attractive stage for immune-assisted attack and
herefore a preferred target for vaccine development.
Fig. 2A gives a schematic representation of the most relevant
pz proteins involved in invasion of hepatic cells. The circumsporo-
oite protein 1 (CSP-1), thrombospondin-related associated protein
TRAP), sporozoite threonine and asparagine rich protein (STARP),
porozoite proteins essential for cell traversal 1 and 2 (SPECT-1
nd 2), cell traversal protein for ookinetes and sporozoites (Cel-
OS), sporozoite protein with an altered thrombospondin repeat
SPATR), multi-domain sporozoite surface protein MB-2, merozoite
apping protein 1 (MCP-1), sporozoite-induced associated proteins
 and 2 (SIAP 1 and 2) and thrombospondin-related sporozoite pro-
ein (TRSP) have been the most studied of the around 30 molecules
escribed to date as being speciﬁc for these functions, as reviewed
n [13,14].
During a single week Spz reproduce 30,000 times within hepatic
ells where they are inaccessible to the immune system (camou-
aging), producing molecules speciﬁc for this stage, such as liver
tage antigen 1–3 (LSA 1–3), and sporozoite-associated liver stage
ntigen (SALSA) [13] (Fig. 2A) and changing their morphology into
 piriform structure (Fig. 1D) called a merozoite (Mrz). The Mrz
xpresses different molecules enabling it to roll over the red blood
ell (RBC) surface (Fig. 1E), reorientates towards the apical end to
orm a tight junction complex and releases microneme proteins
Fig. 1F) for invasion of the RBC in a receptor-ligand type interaction,
 process taking about 180 s.
Each Mrz  can invade a RBC to initiate its reproductive cycle;
his lasts 48–72 h, produces around 30 new Mrz  and causes
BC death [4,5]. So far, only an innate and/or acquired immune
esponse or antimalarial drug treatment can stop this process. The
elease of detritus produced during intracellular growth (Fig. 1G),
he destruction of RBC, vascular occlusion and interaction with
ytokines produces symptoms and signs of the disease (fever, nau-
ea, headache, shivering, anaemia, thrombocytopenia) and maylead to severe malaria and death [20] which, as mentioned before-
hand, claims ∼650,000 individuals, mainly children aged <5 years
old, each year.
The molecules involved in this stage which have been most stud-
ied to date (their schematic representation is depicted in Fig. 2B)
include merozoite surface proteins 1–11 (MSP-1 to -11), erythro-
cyte binding antigens having different molecular weight (EBA 175,
140, 181), erythrocyte binding ligand (EBL), apical merozoite anti-
gen 1 (AMA-1), reticulocyte binding homologue proteins 1–5 (Rh
1–5), membrane bound proteins Pf 12, 38, 42, 92, 113, serine
repeat antigen 5 (SERA 5), ring erythrocyte surface antigen (RESA),
histidine-rich proteins I and II (HRP I and II), proteins encoded by
the cytoadherence-linked asexual genes 3.2 and 9 (CLAG 3.2 and 9)
and rhoptry proteins 1–5 (Rhop 1–5) [15].
When Spz and Mrz  are free and have not yet invaded their
respective target cells (camouﬂaging themselves inside the host
cells, like Odysseus’ colleagues in Polyphemus’ cave), the plasmodia
are susceptible in these few moments to attack by the immune sys-
tem from the outside. The search for vaccines (weapons) targeting
proteins from such stages has thus become a priority. Some exam-
ples are given in [21–26]. However, the microscopic Odysseus has
many strategies in store for escaping immune pressure [2,12,27].
3. Smokescreens and genetic variability
Many soluble proteins released into the bloodstream have no
recognised function regarding invasion (glutamate-rich protein
(GLURP), HRP-II, etc) [28,29], whilst others, on being processed,
have highly antigenic and/or immunogenic repeat amino acid
sequences (tandem repeats) but no protectogenic activity since the
antibodies induced by them do not impede invasion and thus infec-
tion. Many of them are thus considered decoys or smokescreens
[30,31], this being one the main mechanisms used by the para-
site for evasion. Tremendous genetic variability in unstable genetic
areas (those susceptible to mutation) which enable a protein’s
essential structural and antigenic characteristics to change dramat-
ically and thereby evade previously induced immune responses,
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Fig. 2. P. falciparum Spz and Mrz  proteins involved in hepatocyte and RBC invasion. (A) Schematic representation of 15 Pf Spz invasion-associated and cell traversal-related
proteins. Adapted from [13,14]. (B) Schematic representation of 35 Pf Mrz proteins involved in RBC invasion (due to its length, Rh2a is displayed three times). Location of
HABPs  (black) regarding binding to RBCs and HepG2 cells; molecular mass and sequence accession codes are also indicated. Adapted from [12–15,98]. The native amino
acid  sequences for cHABPs are shown in Table 1. For A and B, the bar length corresponds to approximate molecular weights. The colour code is described in the box. GPI:
glycosylphosphatidylinositol anchor.
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s another mechanism frequently used by the parasite to escape
mmune pressure [32–36]. Based on the number of point mutations
xpressed, it has been calculated that P. falciparum has thousands
f genetic variants, thereby making it very difﬁcult to control using
iologically derived vaccine strategies, including whole genetically
ttenuated parasites, recombinant proteins, DNA fragments, and
ector-based vaccines [24,26]. Moreover, our Lilliputian Odysseus
ngages in yet another subtle strategy, as described below.
.1. cHABPs are immunologically silent or invisible
Our group (HC, MAP  and MEP) has developed and used a highly
peciﬁc, sensitive and robust methodology throughout the last 25
ears [37–39], making use of 15–20 amino acid-long, chemically
ynthesised, non-overlapping peptides covering the whole protein,
o identify high activity binding peptides or HABPs from the most
elevant functional proteins from Plasmodium falciparum parasite
Fig. 2 and Table 1) involved in invasion to host cells, reviewed
n [13–15,38,40]. These HABPs engage in receptor–ligand inter-
ctions, as demonstrated by highly speciﬁc and strong binding
apacity to host cells, invasion inhibition, susceptibility to enzyme
reatment, and crosslinking with pertinent host cell membrane
eceptors. Many HABPs are derived from conserved protein regions,
nd are named conserved high activity binding peptides or cHABPs
s they have no mutations or changes in the amino acid sequences
n a large panel of molecules from strains from different parts of the
orld, as reported in the PlasmoDB database [25]. These cHABPs
erform biological functions involved in P. falciparum invasion and
nfection of host cells (Fig. 2), and therefore would be ideal vaccine
andidates. However, they have the property of being immunolog-
cally silent (i.e. they do not induce any type of immune response)
s illustrated in Fig. 3 [41], and as will be analysed atomically and
mmunogenetically later on.
This immunological silence is different from prior work by
li Sercarz’s group on “cryptic epitopes” (from the old Greek
óς——hidden; in science, dark, enigmatic or camouﬂaged)
erformed long ago, deﬁned as conserved amino acid sequences
erived from any molecule involved or not in invasion or infec-
ion of host cells (like hen egg lysozyme (HEL)), that are hidden
nside, camouﬂaged or covered by other protein structures or
ven amino acids that cannot be seen by experimental models or
uman immune system with certain genetic background, suggest-
ng “holes” in the immune system [42–44].
This immunological silence was discovered by us 25 years ago
hen using ELISA for analysing the reactivity of chemically synthe-
ised 20 mer, non-overlapping, sequential peptides derived from a
arge panel of proteins with sera taken from individuals who had
ecovered from several episodes of malaria (1–3 times) caused by
. falciparum together with hyper-immune sera from Aotus infected
everal times (from 1 to 5) with the highly virulent Aotus-adapted P.
alciparum FVO strain (making them resistant to intravenous infec-
ion with more than 500 million infected erythrocytes (iE) for this
train). It was found that all of them had developed antibodies
gainst distinct molecules and their fragments, mainly the variable
nes, but never against cHABPs (Fig. 3A, coloured in green in the
SP-2 molecule as one example, unpublished results).
This suggested that cHABPs were immunologically silent or
nvisible to the immune system and that protective immunity was
train-speciﬁc, since further challenge of these resistant monkeys
ith a different P. falciparum strain (FMG) induced the disease in
hese monkeys, even with a small dose (<10,000 iE), despite the
ery high antibody titres against other peptides from the same
r different proteins but NOT against cHABPs from any of the
nalysed molecules. The seminal results by other groups from ﬁeld-
tudies demonstrating that the immune response against malaria 33 (2015) 7525–7537
was strain-speciﬁc [45–50] (Fig. 3A) were thus corroborated by a
different approach.
The immunological invisibility or silence (tricking Polyphemus)
of cHABPs presented the problem of how to induce a strain-
transcending universal immune response which would include all
parasite strains.
3.2. mHABPs as breakers of immunological silence
Based on the altered peptide ligand (APL) concept postulated by
Paul Allen (1989) stating that replacing some residues modiﬁed
their immunological performance (increasing, reducing or even
suppressing it) [51,52], cHABPs’ critical residues in binding to RBC
(those whose binding capacity became reduced by more than 50%
when modiﬁed by glycine analogue replacement scanning methods
(Fig. 5) [15,39]), our group dedicated its efforts towards identifying
the universal rules for replacing cHABPs’ critical binding residues
to bypass the immunological silence and induce a heightened pro-
tective immune response against malaria in Aotus monkeys.
All amino acid physicochemical parameters were analysed (size,
volume, charge, residue location in the peptide, etc) and around
40,000 (15–20 mer  long) peptide analogues were synthesised,
and a subset of around 4000 were tested in Aotus monkeys,
thereby determining which amino acid should replace another for
inducing immunogenicity,  i.e. maximizing antibody responses by
ELISA against native and/or modiﬁed peptides (not shown here),
by immunoﬂuorescence antibody test (IFA) against the whole
parasite or by Western blot (WB) against merozoite lysate or
recombinant fragments from the corresponding proteins, but more
importantly, for inducing protectivity, i.e., inducing a protective
immune response against experimental challenge with an intra-
venous inoculation of 100,000 freshly infected erythrocytes from
the Aotus-adapted P. falciparum FVO strain [53].
This extensive and thorough chemical, biological and immuno-
logical analysis showed that the key substitutions were to replace
amino acids by others having opposite polarity, such as W↔Y,
F↔R, I or L↔H, M↔K,  V↔Q or E, P↔D, C↔T, A↔S, which allowed
preservation of critical binding residue volume, mass and surface
[11,12] (Table 1). This unique, striking and straightforward strat-
egy broke immunological silence and led to obtaining modiﬁed
HABPs (mHABPs) which were highly immunogenic, as assessed
by high antibody titres against the original parasite proteins by
IFA, or when expressed as recombinants, or when present in Mrz
lysates (as determined by WB). These mHABPs induced full protec-
tive immunity (the absolute absence of the parasite in the blood) in
Aotus (Table 1) [53–57], and were deﬁned as immune protection-
inducing protein structures (IMPIPS) [19]. Whether or not a
mHABP was also an IMPIPS depended upon the stereo-chemical,
and topological characteristics induced by these modiﬁcations in
the peptide: some mHABPs were not immunogenic [12], others
induced short-lived antibody responses but were not protective
[32], others induced long-lasting antibody responses but were also
not protective [33], whilst some were IMPIPS, with these various
characteristics depending upon the 3D structural conformation of
the peptide, to be analysed in detail further on. Therefore all IMPIPS
are mHABPs but NOT all mHABPs are IMPIPS.
4. Immunogenetic analysis
The protective effect of humoral immunity against clinical
malaria was described more than 50 years ago [58], with a highlight
being the genetic control of such responses by major histocompat-
ibility complex (MHC) molecules expressed by antigen-presenting
cells, particularly class II molecules (MHC II, or HLA-DR in
humans).
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Table  1
Sequences for cHABPs and their immunogenic protection-inducing analogues (mHABPs) from the most relevant P. falciparum Mrz  (left) and Spz(right) proteins involved in
host  cell invasion and endothelial cell adhesion (Fig.2). Critical binding residues in cHABPs and those that were changed in protective mHABPs are highlighted in bold. II and
III:  Antibody titres (in parenthesis) assessed by IFA 20 days after the second and third immunisations, respectively. Those monkeys displaying these antibody titres were the
same  ones showing strong reactivity by ELISA (not shown) and WB with schizont protein lysate or recombinant fragments containing the amino acid sequences from where
the  mHABPs were derived. They are the same fully protected monkeys in experimental challenge with the Aotus-adapted virulent P. falciparum FVO strain. For both tables,
the  preﬁx represents the amount of monkeys which developed these antibody titres. The big black dots indicate those native or modiﬁed HABPs for which their 3D structure
was  assessed by 1H NMR. Only the most representative immunogenic protection-inducing mHABPs from each family are shown. For Table regarding Mrz  proteins (adapted
from  [12]), Prot: fully protected monkeys. DR: HLA-DR 1* allele with which each HABP was found to have high binding capacity.
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Fig. 3. (A) MSP-2 peptides antigenicity. Example of reactivity of human and Aotus monkeys’ hyperimmune sera against PfMSP-2 peptides (left). On the right, the MSP-2
peptides binding proﬁle to RBCs is shown. Humans were recovered from several episodes of malaria (1–3 times) caused by P. falciparum and Aotus were infected several times
(from  1 to 3) with the virulent Aotus-adapted P. falciparum FVO strain. The sera (analysed by ELISA with many Spz and Mrz proteins, 20 mer long, sequential, non-overlapping
peptides) recognised variable sequences (yellow), but no cHABPs (green), which allowed us to recognise the immunological silence of cHABPs. (B and C) Immune evasion
mechanisms. Space ﬁlling 3D structure of AMA-1 (PDB: 1Z40) and EBA-175 (PDB: 1ZRL). Protein location of cHABPs 4313 (yellow) and 4325 (dark blue) in AMA-1 and 1783
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Studies by one of our group (MEP) at Rockefeller University in
uman immunogenetics (almost 40 years ago) led to establishing
n association between rheumatoid arthritis, systemic lupus ery-
hematosus [59] and infectious diseases like chronic Lyme arthritis
60] and rheumatic fever [61] with HLA-DR complex molecules. A
earch for a similar association with the ﬁrst chemically synthesised
alaria vaccine (SPf66) [62,63] led to identifying a relationship
etween HLA-DR*04 genetic trait and the absence of antibody
roduction or protection against malaria, as well as the predomi-
ance of TCRV10, 11 or 3 expression in these individuals [64,65].
The only methodology available at the time for determining
HABPs’ experimental binding capacity to puriﬁed HLA-DR1*
olecules was adopted, working with a limited number of these
olecules (HLA-DR1* 0101, 0301, 0401, 0701 and 1101) which
ere representative of the main haplotypes (set of alleles) HLA-
R1, DR52, DR53 [66]. Most cHABPs did not bind to these molecules
r did so promiscuously, binding to several of them, whilst many
HABPs adopted speciﬁc allele binding capacity (more than 50%
isplacement of control peptide), clearly suggesting that the mod-
ﬁcations so made had induced structural changes regarding the
peciﬁcity of binding to these molecules, making them highly
peciﬁc for and having great afﬁnity for a determined HLA-
R. This partly explained why these mHABPs’ speciﬁc allelekest the most variable ones), showing their localisation in regions opposite or very
characteristics and their immunogenic and protection-inducing
ability were revealed in just some of the immunised monkeys
[11–13,53–57,67,68].
5. The Aotus monkey as the ideal model for anti-malarial
vaccine development
This small New World primate, weighing around 800 g, is indige-
nous to South-America; it was discovered in Colombia by Humboldt
in 1812 and identiﬁed by Carl Johnson (Rockefeller Foundation)
in 1966 as a species which is highly susceptible to developing
human malaria [69]. Since these monkeys can be easily infected
with small doses of any human malaria infected RBCs and alterna-
tively their infected blood can transmit the same malaria to human
volunteers, one of the main Robert Koch’s principles is fulﬁlled.
It thus became the appropriate experimental model for develop-
ing drugs and vaccines against this disease [70]. Being endemic in
Colombia, our Institute took this monkey as the ideal model for
developing an anti-malarial vaccine and an experimental station
was created in January 1980 in the Amazon Jungle, in Leticia,
Amazonas, Colombia, where they have a population density of
25.9–45.0 monkeys per km2, therefore being classiﬁed as a non-
endangered species. Colombia’s ofﬁcial environmental authority
accine
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CorpoAmazonia) requires that monkeys received in its pres-
nce be tattooed and classiﬁed under supervision by biologist
nd veterinarian ofﬁcials. Once experiments have been completed
immunisation and challenge), the monkeys are kept in quarantine
nder the oversight of an expert primatologist and then returned
alaria-free to their native habitat in excellent physical condition,
lso under ofﬁcial supervision.
The seminal results following the development of SPf66 (the ﬁrst
hemically synthesised vaccine, tested in large human groups in
ifferent parts of the world) [71–74] led to molecular biology (DNA
equencing) being used for characterising the genes from more than
0 of this monkey’s main immune system molecules in our institute
rom 1990s onwards, a task undertaken by Dr. Alberto Moreno, Dr.
arlos Suarez and Dr. Manuel Alfonso Patarroyo’s team, originally
ith the cooperation of Professor Gerd Pluschke and Dr. Claudia
aubenberger. More than 98% identity has since been found with
uman orthologues in some Aotus proteins, such as the cytokines,
nd other cluster of cell differentiation (CD) interacting molecules.
ikewise, 84–96.5% similarity with its human counterpart has been
ound in other molecules having high genetic variability, such as
HCI II and , , 	 and 
 T-cell receptors [75–78], similar to the
ariability found amongst different human ethnic groups, suppor-
ing the relevance of using this monkey in developing vaccines for
uman use.
. If you don’t understand the function, analyse the
tructure and vice versa
Since 1996, we have identiﬁed ∼300 cHABP and mHABP 3D
tructures, using Kurt Wütrich’s 1984 methodology for determin-
ng the three dimensional (3D) structure of peptides and proteins
y 1H NMR  [79]. These ﬁndings, combined with functional, biologi-
al and immunological studies of these molecules, have formed our
pproach to rational vaccine design [11,12,56]. Accordingly, “If you
on’t understand the biological and/or immunological function,
nalyse the structure and vice versa” has become a “workhorse”
hrase in our institute. Our studies have conﬁrmed what has been
bserved by circular dichroism (CD), where most cHABPs show -
elical or -sheet, turns or random structures, whilst most mHABPs
isplaying IMPIPS activity have a particular polyproline type II left-
anded-like (PPIIL) structure, a molecular conformation described
n 1993 by Adzhubei and Sternberg [80]. This PPIIL helix has been
haracterised by having an extended left-handed structure, having
.1 A˚ per residue, 3 residues (2.5–4.0) 9.12 A˚ per pitch, the absence
f intra-chain H-bonds, side-chains located perpendicularly to the
eptide backbone and −90 ± 15◦ and +135 ± 15◦  and   angle
otation, respectively. A short while afterwards, Jardetzky (1996)
ound that this structure (PPIIL) had the same characteristics as the
nterotoxin B peptide which ﬁtted into the HLA-DR1* 0101 pep-
ide binding region (PBR) groove [81] and, a few years later, other
roups conﬁrmed their ﬁndings [81,82]. This provided the impetus
or us to begin our own 1H NMR  3D studies of cHABPs and mHABPs
n 1996.
Based on atomic knowledge of 3D structure (by X-ray crystal-
ography) of HLA-DR molecules (elegantly described by structural
mmunologists) [81,83] and of our own peptides (determined by
H NMR), a striking ﬁnding was made: cHABP amino acids DID NOT
IT into the HLA-DR1* PBR groove. This was due to cHABPs’ short,
ompact, rigid, right-handed, -helical structure (since left-handed
tructures are energetically unfavourable) having 1.5 A˚ per residue,
nter-atom H-bonds,  = −60◦, −90◦,   = −40◦, −60◦ angle limits
nd 3.6 amino acids per pitch (in essence ∼12 A˚ distance between
he 9 residues the PBR can accommodate). Some other cHABPs dis-
layed very long extended structure in the -sheets or showed a
olded -turn structure (having 2 residues per turn and H-bonds 33 (2015) 7525–7537 7531
between i + 1 and i + 2) or displayed totally unordered (random)
structures, too long or not structured enough to ﬁt into the HLA-
DR1* PBR. Meanwhile, immune protection inducing mHABPs
displayed PPIIL conformations involving an appropriate 26.5 ± 3.5 A˚
distance (∼3PPIIL turns, since each turn had a 9.1 A˚ distance) [84]
so that the most distant residues perfectly ﬁtted in HLA-DR1* PBR
position 1 (position is shown by p from now on) and p9, anchoring
mHABPs to these class II molecules and proper N and O backbone
atom orientation, as discussed later [55,56,85,86]. This data clearly
showed that these mHABPs, displaying such stereochemical char-
acteristics, could become IMPIPS since they ﬁtted perfectly well
into HLA-DR1* PBR to properly activate immune protective activ-
ity.
7. Charge and volume of the amino acids ﬁtting into
HLA-DR1 pockets
As well as the aforementioned appropriate distance for an HLA-
DR1*-binding molecule (i.e. a mHABP), the immune response is
characterised by the speciﬁcity of the stereo-electron character-
istics determining such interaction. A very brief description, with
pertinent examples, follows. The amino acids forming Pocket 1 of
the HLA-DR1* PBR (F24, F32, I31, W43,  I69, V85, G6V,
F89 and V91) (Fig. 4A1 and C1), due to their hydrophobic char-
acter and to aromatic residues’ resonant  bonds (in bold) making
this pocket deep and hydrophobic (Fig. 4A2), cause Pocket 1 (spe-
ciﬁc pockets are referred to by P from now onwards) to display a
preference for aromatic residues such as Trp, Phe and Tyr, establish-
ing strong, resonant – bond interactions [83,87] and allowing a
peptide to ﬁt correctly. This pocket displays the dimorphic vari-
ant G86V; taking into account that V (140.0 A˚3) is bulkier than
G (60.0 A˚3), this physicochemical volumetric difference sterically
impedes the ﬁt of large aromatic amino acids like Trp and Tyr, but
due to its apolarity receives large apolar residues, such as Leu, Ile,
Met  and Val. This variant is present in all HLA-DR* allele lineages
(Fig. 4C1).
Regarding P4, where most allelic variants are present, the
genetic polymorphism is most prominent in the -chain (since
the -chain is invariable). Tremendous genetic polymorphism in
the amino acid charge and volume is found, mainly in 9, 11,
13, 26, 28, 30, 70, 71, 73 and 74 (Fig. 4A1 and C2)
[87–89]. Such combinations of different amino acid changes in
these positions generate a huge immunological repertoire to accept
the different microbial and self-epitopes. Thus, as an example,
in individuals having the HLA-DR1* 0301 genetic trait involv-
ing amino acids K71 and R74 (voluminous, positively charged
residues), such variants determine that this pocket be small and
positively charged, only accepting small, oppositely charged (neg-
ative) amino acids, such as Asp; by the same token, individuals
expressing HLA-DR1* 1501 (DR2) involving small apolar residues
A71 and A74, have a spacious apolar P4, thereby allowing large
apolar amino acids (Phe, Leu and Ile) to ﬁt (Fig. 4A1 and C2) [87,88].
There are many more examples for each one of the HLA-DR1*
allele lineages.
Similarly, regarding P6 for HLA-DR1* 0301 individuals, the
small size of S11, S13 and E9 forming it and the negative charge
of amino acids E11 and D66 and the H-bond network established
with N62 and N69 create a highly polar, spacious, negatively
charged P6 where complementary large, positively charged amino
acids such as Lys, Arg and/or His ﬁt perfectly (Fig. 4A1 and C3) [87].
By contrast, in P6 and as a consequence of apolar amino acids
V11, F13 and W9 being voluminous in HLA-DR1* 0101 indi-
viduals, an extremely small and apolar niche is created in this
pocket where only small, apolar amino acids such as Gly, Ala, Pro
or Ser ﬁt (characteristic for this allele) (Fig. 4B and C3).
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Fig. 4. Structural features of MHC-II, TCR and MHC-II/peptide/TCR interaction. (A1) Ribbon representation of the HLA-DRB1*0401 (PDB accession number 2SEB) molecule
showing the -chain in pink and the -chain in light blue [89]. Residues forming Pocket 1 are shown in fuchsia, Pocket 4 in blue, Pocket 6 in light brown and Pocket 9 in green.
Red  balls show residues establishing H-bonds with peptide backbone atoms [89]. (A2) The space ﬁlling ﬁgure shows the depth of Pockets 1 (fuchsia) and 9 (green), surface
localisation of Pockets 4 (blue) and 6 (light brown) on the HLA-DR1*0401 PBR platform [89]. (B1) Superimposition of mHABP 25608.37 (CSP HABP 4383) backbone structure
(determined by 1H NMR [85]) on HLA-DR1*0401 determined by X-ray crystallography. (B2) Superimposition of mHABP 10014.35 (MSP-1 1585 HABP) backbone structure
(determined by 1H NMR) on HLA-DR1*0101 [86]. For B1 and B2, inter-atom distances (expressed in Angstroms (Å)) between peptide backbone and HLA-DR side-chain atoms
are  shown as small silver balls. (C1–C4) Surface representation of HLA-DR1*03 (PDB accession number 1A6A) Pockets 1, 4, 6 and 9 (left) and HLA-DR1*15 (PDB accession
number 1BX2) (right) [87,88,100]. Regarding each Pocket, it can be seen that PBR sequence variation dramatically affects its volume and therefore the size and polarity of
any  residue which might ﬁt into it. The G86V dimorphic difference present in all allele families is shown in C1 in red. Differences between human and Aotus are shown
in  C2–C4 in fuchsia, their peripheral location regarding peptide-binding residues led us to suggest that such substitutions do not affect peptide binding. (D) MHCII–24112
(MSP2  4044 cHABP)–TCR trimolecular complex formation associated with sterilising immunity. Docking and energy minimisation studies for this mHABP with a previously
reported HLA-DR1*0401–HA1.7 peptide–TCR complex structure [101,102]. The HLA-DR1*04 and TCR V CDR3 amino acid sequence variations identiﬁed in protected
Aotus  monkeys were used to determine spontaneous H-bond formation, van der Waals (vdW) interactions (small black dots), residue orientation and intermolecular distance
differences between interacting atoms. (E1) H-bonds formed by mHABP24112- TCR interaction. (E2) Side view of the HLA-DR1*0422–24112–TCR trimolecular complex
[102]. (F) Orientation and steric-electron effects for mHABP 25608.37 residues. For Phe1 hybrid sigma (
) orbitals (yellow),  and p orbitals perpendicular to them (red,
blurred balloons) are shown. Ser2 (red), Leu3 (blue), Glu5 (rose), Pro7 (grey) and Asp8 (yellow) are pointing upwards towards the TCR [90,103]. The bottom front view clearly
shows these residues’ orientations: p2 (Ser) towards the right-hand side, p3 (Leu) towards the left, p5 (Glu) perpendicular to the peptide backbone, p7 (Pro) towards the
right  and p8 (Asn) towards the left. All these stereochemical dispositions determined by their X1 and X2 angles’ gauche+ orientation to allow perfect TCR diagonal orientation,
were  assessed experimentally by 1H NMR  for each one of the cHABPs and mHABPs (∼300).
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By the same token, the genetic dimorphism in P9 involving a
alt bridge being formed between R76 and D57 determines this
ocket’s size and limits; consequently, P9 in individuals having
enetic variation 57D+ accepts small amino acids whose polarity
epends on the presence of other polar amino acids, such as E9,
9 or W9 (Fig. 4A1 and C4), thereby receiving charged amino
cids, such as Lys, Arg or His for E9, or Gly, Ser or Asp for K9,
hilst the apolarity and large size of W9  determine that the vol-
me  of an apolar amino acid ﬁtting into P9 be small [87,88], and
o on, successively for each and every HLA-DR1* allele variant.
ll these genetically determined physicochemical characteristics
Table 2
Conformer dihedral angle measurements for some mHABPs as determined by 1H
and  -turn regions are highlighted in grey, green and yellow, respectively. Deep 
of  these rotamers [85]. 33 (2015) 7525–7537 7533
in P1, 4, 6 and 9 and their combinations are some of the key fac-
tors for the exquisite and huge speciﬁcity of the immune system
recognition, extremely relevant for vaccine development.
8. Anchoring mHABPs to the HLA-DR* PBR
The distance established between the farthest atoms in P1–9
(26.5 ± 3.5 A˚), together with the volume and electron charge of the
residues ﬁtting into P1, 4, 6 and 9, determine the precise location
of mHABPs in the PBR, thereby enabling their stable anchoring.
Such binding is mediated by H-bonds established between O and
 NMR. The HLA-DR molecule for each mHABP is indicated (top). PPIIL, L
purple shows the X1 and X2 rotation determining the gauche +orientation
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Fig. 5. Flow-chart for developing a fully protective complete malarial vaccine. The elegant work by many other groups has identiﬁed the Spz and Mrz derived proteins
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aelevant in P. falciparum invasion and infection to host cells. Based on this informat
rotective complete minimal subunit based multistage multi-epitope chemically sy
 free electron pairs from mHABP backbone atoms with oppo-
itely charged free electrons located in HLA-DR1 amino acid
ide-chain atoms (Q9, N62, N69 and N82). This forms 9–11
tom ring structures having double H-bond and single H-bond
S53, K71, W6) binding, establishing 9–13 H-bonds strongly
nchoring mHABPs to the ﬂoor of the PBR thereby stabilising its
resence for ∼120 h, enabling presentation to the T-cell receptor
TCR). This stable and long-lasting HLA-DR1*-mHABP complex is
 key factor in antigen presentation to the TCR and the induction of
n appropriate immune response [12,56,83,85,86,90,91].
. Side-chain orientation for making contact with the TCR
After binding and stabilising HLA-DR or MHC  II molecules in
he PBR, an appropriate orientation must be ensured for the side-
hains of solvent-exposed or upwardly orientated amino acids to
ake contact with the TCR (Fig. 4D and E). After many very frus-
rating monkey trials, when these individually highly immunogenic
nd protection inducing mHABPs were mixed yielding completelyemically synthesised peptides follow the path shown in this chart to obtain a fully
ised malarial vaccine.
negative results, we  found that the rotamer orientation of TCR-
contacting residues was the critical factor for generating protective,
long-lasting immunity in response to a multi-epitope vaccine
[12,57,91]. This meant that the rotamer orientation and charge
of side chains from TCR contacting residues had to be taken into
account, such that a residue located in p2 must be polar and ori-
entated towards the right, a residue located in p3 apolar towards
the left, a residue located in p5 polar and perpendicular to the
axis of the mHABP backbone, a residue located in p7 apolar and
towards the left and, for p8, towards the right. This is also asso-
ciated with p2, p3, p5, p7 and p8 side-chain X1, X2 and X3 angle
orientation, speciﬁc rotamer dispositions being adopted where X1
angles in p3 and p7 must adopt a gauche+ position, the same as most
X2 angles in p5, for inducing sterilising protective immunity [90]
(Fig. 4F and Table 2A). This enabled the mixing of several IMPIPS,
a critical step in the pursuit of a highly protective subunit mixture
malaria vaccine.
The foregoing analysis shows that successful subunit vaccine
design, particularly regarding malaria caused by P. falciparum,  relies
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pon adherence to strict stereo-electron and physical-chemical
ules for peptide conﬁguration that determine biological function,
mmunogenetic speciﬁcities and immunological outcome (Fig. 5).
e believe that this is a fundamental discovery, and that it will
llow the circumvention of one of the most devious adaptations of
he malaria parasite for evading host immunity. Our microscopic
dysseus likely still has many as-yet-unknown stratagems but,
opefully, in a not too distant future, we can understand them all
nd defeat him.
0. Conclusions and perspective:
A large body of immunological, functional and structural evi-
ence has demonstrated that conserved high activity binding
eptides, or cHABPs, which are directly involved in biological
unctions mediating invasion or infection of host cells, are immuno-
ogically silent structures (Aza J. and Patarroyo ME., manuscript in
reparation). On the other hand, variable amino acid sequences in
he same molecules are highly immunogenic, but NOT protection-
nducing, partly due to their tremendous genetic variability and
he strain speciﬁcity of the immune response they elicit, and
artly due to their stereochemical and topological location in such
nvasion-relevant molecules. These highly polymorphic regions are
tructurally far from the cHABPs, as originally suggested by Sing
t al. [41] (Fig. 3A and C gives examples) and recently demon-
trated by us in several malarial proteins for which the 3D structure
as been determined. To render cHABPs into highly immuno-
enic and/or protection inducing immunogens (IMPIPS), with a
oal to achieve strain-transcending immunity, speciﬁc modiﬁ-
ation of certain residues need to be made; if done properly,
his allows them to ﬁt perfectly into the HLA-DR1*-mHABP-TCR
omplex.
We have described the structural, topological and stereo-
lectronic rules or principles that enable the transformation of
ost cell invasion functionally relevant cHABPs into potent IMPIPS.
hese include speciﬁcations for residue charge and volume (ana-
ysed above), a 26.5 ± 3.5 A˚ distance between the farthest IMPIPS
esidues ﬁtting into HLA-DR1* molecule PBR P1–P9, and speciﬁc
eptide bond  and   angle plane rotations to form or contain
PIIL structures to ensure appropriate peptide backbone and O and
 atom orientation. These rules allow for appropriate anchoring
o HLA-DR1*molecules. There must also be speciﬁc topologi-
al orientation of residues pointing away from the PBR, such as
2 towards the right-hand side, p3 perpendicular or toward the
eft, p5 perpendicular or lightly tilted towards the left, p7 above
ut not clearly deﬁned and p8 towards the left-hand side. Fur-
hermore, IMPIPS demand a speciﬁc electron landscape, involving
on-bonding electron pairs with p orbitals in p2, p5 and p8, while
3 and p7 are dominated by residues having 
 orbitals. This enables
trong, speciﬁc interaction for ∼120 h with the TCR to form an
ppropriate HLA-DR1*-IMPIPS-TCR complex. If these principles
re not adhered to, inappropriate amino acid orientation will lead
o suppression, blocking or impeding the appropriate ﬁt of the
HABP, resulting in an unstable complex and therefore a muted
on-protective immune response.
These rules or principles provide a rational methodology (Fig. 5)
o design highly immunogenic, fully protective, multi-epitope,
ultistage, minimal subunit-based, chemically synthesised pep-
ides for malaria vaccines, here named IMPIPS. Our ﬁndings give
trong support to our functional–structural approach,  and open
he gate for developing chemically synthesised vaccines in other
reas, with malaria representing just one of many infectious agents
here these principles could be applied.
The appropriate mixture of IMPIPS therefore should circumvent
he interference, blocking or suppression barriers erected by the
alaria parasite. We  propose that if an IMPIPS mixture covered the 33 (2015) 7525–7537 7535
full repertoire of HLA-DR1* genetic variants, it could achieve the
long sought-after dream of a fully protective malaria vaccine.
11. Colophon
The Odyssey narrates Odysseus’ adventures up to the point of
his return to Ithaca, but Homer does not tell us what happened
afterwards; one could hope that, like the tale of such an astute and
cunning Greek warrior, the history of malaria becomes a story of the
past when the rules and principles outlined above for controlling it
have been adopted.
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